Finance

Lists
Q3 2026 earnings • released • EPS miss -29,02% • Revenue beat +5,62%
See results
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
USD 3,87
0,00%
(0,00) 1D
USD 3,99
+3,10% (+0,12)
Pre-market
Closed: 11 Nov., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Mkt. cap
66,37 m
Avg. vol.
1,06 m
Volume
4,12 k
52-wk high
USD 20,56
52-wk low
USD 4,00
EPS
-USD 12,92
Beta
1,90
Shares outstanding
19,43 m
No. of employees
142
Mkt. cap
66,37 m
Avg. vol.
1,06 m
Volume
4,12 k
52-wk high
USD 20,56
52-wk low
USD 4,00
EPS
-USD 12,92
Beta
1,90
Shares outstanding
19,43 m
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, New Jersey, Verenigde State van Amerika
SectorHealth Care
Industry-
Websitetonixpharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current USD 3,87
USD 40,00 (+933,59%)
Average
USD 23,50 (+507,24%)
Lowest
USD 14,00 (+261,76%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Maintained
USD 40,00
+933,6%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
USD 18,00
+365,1%
11/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
USD 14,00
+261,8%
11/09/2026
Stacy Ku
TD Cowen
Buy
Maintained
USD 22,00
+468,5%
10/21/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
USD 37,00
+856,1%
03/16/2026
Last report
09 Nov. 2026
Fiscal period
Q3 2026
-USD 2,89 / -USD 2,24
-29,02%miss
Revenue / Est. (USD)
17,23 m / 16,32 m
+5,62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
5,39 m
6,88 m
13,54 m
17,23 m
Cost of goods sold
1,06 m
1,58 m
703,00 k
1,25 m
Cost of revenue
1,06 m
1,58 m
703,00 k
1,25 m
Research and development expenses
16,94 m
18,21 m
19,42 m
25,82 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,68 m
28,62 m
35,96 m
45,59 m
Operating expense
52,62 m
46,84 m
55,38 m
71,41 m
Total operating expenses
53,68 m
48,42 m
56,08 m
72,67 m
Operating income
-48,29 m
-41,54 m
-42,54 m
-55,43 m
Other non operating income
32,00 k
-3,00 k
551,00 k
741,00 k
EBT including unusual items
-46,91 m
-40,19 m
-40,55 m
-53,33 m
EBT excluding unusual items
-46,91 m
-40,19 m
-40,55 m
-53,33 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-46,91 m
-40,19 m
-40,55 m
-53,33 m
Net profit margin
-870,32%
-584,38%
-299,41%
-309,44%
Earnings per share
-3,98
-2,93
-2,47
-2,89
Interest and investment income
1,34 m
1,35 m
1,43 m
1,36 m
Interest expense
-
-
-
-
Net interest expenses
1,34 m
1,35 m
1,43 m
1,36 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,80 m
-40,98 m
-41,92 m
-54,79 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme